Altertoxin III is a mycotoxin produced by the fungus *Alternaria alternata*. It has been isolated from various agricultural commodities such as grains, fruits, and vegetables. Altertoxin III exhibits cytotoxic and genotoxic effects, and studies have shown that it can inhibit cell growth and induce apoptosis in different cell lines. Due to its potential health risks, the presence of altertoxin III in food products is of concern. Research on altertoxin III focuses on understanding its biosynthesis pathways, elucidating its toxic mechanisms, and developing methods for its detection and control in food. The compound's ability to inhibit cell growth and induce apoptosis suggests potential applications in anti-cancer research. However, further investigation is needed to determine its safety and efficacy for therapeutic purposes.'
altertoxin III: structure given in first source; isolated from Alternaria species [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 114895 |
| CHEMBL ID | 3338990 |
| SCHEMBL ID | 17860076 |
| MeSH ID | M0143565 |
| Synonym |
|---|
| ccris 2192 |
| altertoxin iii |
| perylo(1,2-b:7,8-b')bisoxirene-5,10-dione, 1a,1b,5a,6a,6b,10a-hexahydro-4,9-dihydroxy-, (1ar,1bs,5ar,6ar,6bs,10ar)- |
| perylo(1,2-b:7,8-b')bisoxirene-5,10-dione, 1a,1b,5a,6a,6b,10a-hexahydro-4,9-dihydroxy-, (1ar-(1a-alpha,1b-beta,5a-alpha,6a-alpha,6b-beta,10a-alpha))- |
| 105579-74-6 |
| SCHEMBL17860076 |
| CHEMBL3338990 |
| Q26840814 |
| 4,9-dihydroxy-1a,1b,5a,6a,6b,10a-hexahydroperylo[1,2-b:7,8-b']bisoxirene-5,10-dione |
| DTXSID50909615 |
| (2s,3r,5r,12s,13r,15r)-8,18-dihydroxy-4,14-dioxaheptacyclo[10.8.1.12,7.03,5.013,15.017,21.011,22]docosa-1(21),7,9,11(22),17,19-hexaene-6,16-dione |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1166445 | Antiviral activity against HIV1 infected in human A3.01 cells assessed as inhibition of viral replication at 1.5 ug/ml | 2014 | Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21 | Altertoxins with potent anti-HIV activity from Alternaria tenuissima QUE1Se, a fungal endophyte of Quercus emoryi. |
| AID1166452 | Therapeutic index, ratio of CC50 for human A3.01 cells to IC50 for HIV1 infected in human A3.01 cells | 2014 | Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21 | Altertoxins with potent anti-HIV activity from Alternaria tenuissima QUE1Se, a fungal endophyte of Quercus emoryi. |
| AID1166451 | Antiviral activity against HIV1 infected in human A3.01 cells assessed as complete inhibition of viral replication at 1.50 uM | 2014 | Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21 | Altertoxins with potent anti-HIV activity from Alternaria tenuissima QUE1Se, a fungal endophyte of Quercus emoryi. |
| AID1166447 | Antiviral activity against HIV1 infected in human A3.01 cells assessed as inhibition of viral replication | 2014 | Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21 | Altertoxins with potent anti-HIV activity from Alternaria tenuissima QUE1Se, a fungal endophyte of Quercus emoryi. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.53) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||